FOXO4-DRI
Senolytic Peptide — Selective Apoptosis of Senescent Cells
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. Developed at the Erasmus MC Medical Center in Rotterd...
Formula
C168H258N44O49S
Molecular Weight
3856.1 g/mol
What is this compound?
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. Developed at the Erasmus MC Medical Center in Rotterdam, it represents a senolytic approach that selectively induces apoptosis in cells that have entered replicative senescence while sparing healthy proliferating cells.
Selective elimination of senescent cells
Reversal of age-related functional decline in research models
Renal function restoration in progeroid mice
Coat density and activity restoration in aged animals
Spares healthy cells via p53 pathway selectivity
Demonstrated senolytic efficacy in vivo
How it works
In senescent cells, FOXO4 binds p53 and sequesters it in the nucleus, preventing apoptosis. FOXO4-DRI displaces p53 from FOXO4 by competing for the FOXO4 binding interface, freeing p53 to translocate to mitochondria and initiate apoptosis. Because only senescent cells accumulate ...
Areas of investigation
Discovery to present
1970s
Discovery
FOXO4-DRI was first identified and characterized in research contexts.
2000s
Research
Preclinical studies expanded across multiple tissue types and disease models.
2010s
Clinical Progress
Early-stage research progressed toward translational and clinical investigation.
2024+
Current Interest
Active research continues with growing scientific interest and expanding publication volume.
Knowledge connections
Explore how FOXO4-DRI connects to mechanisms, research goals, related compounds, and scientific references.
Research calculations
Plan research protocols with precise reconstitution, dosing, and unit conversion tools.
Reconstitution Calculator
Bacteriostatic water ratios
Dose Calculator
Precise microgram dosing
Unit Converter
Syringe unit conversions
Compare with similar compounds
Primary literature
Reference compilation in progress. See research highlights below.
Erasmus MC research demonstrates reversal of chemotoxicity-induced alopecia and frailty in mice
Erasmus MC research demonstrates reversal of chemotoxicity-induced alopecia and frailty in mice
Progeroid mouse models show restored renal function, fur density, and physical activity
Progeroid mouse models show restored renal function, fur density, and physical activity
In vitro senescence assays confirm selective apoptosis of senescent cells versus controls
In vitro senescence assays confirm selective apoptosis of senescent cells versus controls
FOXO4-DRI — Frequently asked
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. Developed at the Erasmus MC Medical Center in Rotterdam, it represents a ... FOXO4-DRI belongs to the Anti Aging research category and is studied for its senolytic peptide — selective apoptosis of senescent cells.
In senescent cells, FOXO4 binds p53 and sequesters it in the nucleus, preventing apoptosis. FOXO4-DRI displaces p53 from FOXO4 by competing for the FOXO4 binding interface, freeing p53 to translocate to mitochondria and initiate apoptosis. Because only senescent cells accumulate FOXO4, healthy cells are unaffected.
Selective elimination of senescent cells. Reversal of age-related functional decline in research models. Renal function restoration in progeroid mice. Coat density and activity restoration in aged animals. Spares healthy cells via p53 pathway selectivity. Demonstrated senolytic efficacy in vivo.
FOXO4-DRI has the molecular formula C168H258N44O49S and a molecular weight of 3856.1 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
Erasmus MC research demonstrates reversal of chemotoxicity-induced alopecia and frailty in mice Progeroid mouse models show restored renal function, fur density, and physical activity In vitro senescence assays confirm selective apoptosis of senescent cells versus controls These findings are based on preclinical and clinical research. FOXO4-DRI is a research compound and these studies do not constitute medical advice.
No. FOXO4-DRI is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
FOXO4-DRI belongs to the Anti Aging category, which focuses on peptides researched for their telomere-supporting, mitochondrial-protective, and senolytic properties aligned with healthy longevity science. You can explore more compounds in this category on the Anti Aging pillar page.
Add to your cart
Select a variant to add FOXO4-DRI to your cart for comparison, protocol planning, and AI-assisted analysis.
Available Variants
Research Disclaimer
FOXO4-DRI is a research compound. All information is for educational and research purposes only. Not intended for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.